Stockscreener 앱 받기
20.56
17.33%
-4.31
시간 외 거래:
20.72
0.16
+0.78%
전일 마감가:
$24.87
열려 있는:
$23.1
하루 거래량:
6.86M
Relative Volume:
2.03
시가총액:
$2.97B
수익:
$62.38M
순이익/손실:
$-101.59M
주가수익비율:
-23.79
EPS:
-0.8644
순현금흐름:
$-139.93M
1주 성능:
-10.69%
1개월 성능:
-18.83%
6개월 성능:
+151.65%
1년 성능:
+1,253%
1일 변동 폭
$19.34
$23.30
1주일 범위
$19.34
$25.76
52주 변동 폭
$1.40
$28.41
Tango Therapeutics Inc Stock (TNGX) Company Profile
명칭
Tango Therapeutics Inc
전화
(857) 320-4900
주소
201 BROOKLINE AVENUE, BOSTON
Compare TNGX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TNGX
Tango Therapeutics Inc
|
20.56 | 3.60B | 62.38M | -101.59M | -139.93M | -0.8644 |
VRTX
Vertex Pharmaceuticals Inc
|
436.95 | 114.32B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
698.25 | 74.74B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
799.32 | 51.13B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.98 | 39.18B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
145.66 | 31.78B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-02 | 개시 | Canaccord Genuity | Buy |
| 2026-02-23 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-08-19 | 개시 | Piper Sandler | Overweight |
| 2024-07-17 | 개시 | Jefferies | Buy |
| 2024-04-04 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 개시 | Piper Sandler | Overweight |
| 2023-12-08 | 개시 | B. Riley Securities | Buy |
| 2022-10-20 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 개시 | SVB Leerink | Outperform |
모두보기
Tango Therapeutics Inc 주식(TNGX)의 최신 뉴스
[SCHEDULE 13G/A] Tango Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Nextech Crossover reports 7.27M-share stake in Tango Therapeutics (TNGX) - Stock Titan
Jefferies downgrades Tango Therapeutics (TNGX) - MSN
Mizuho Raises Price Target on Tango Therapeutics to $30 From $20, Keeps Outperform Rating - Moomoo
TNGX Stock Crashes 20% After Reporting $0 Revenue In Q1 — But Analysts Still See Massive Upside - Stocktwits
TNGX Maintained by Mizuho -- Price Target Raised to $30 - GuruFocus
Woodline Partners reports 8.0M-share stake in Tango Therapeutics (TNGX) - Stock Titan
RTW Funds disclose 13.3M shares in Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
This Alumis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift By Investing.com - Investing.com Australia
Piper Sandler downgrades Tango Therapeutics stock rating on strategy shift - Investing.com UK
Tango Therapeutics is the best performing healthcare stock in March - MSN
TNGX Downgraded by Jefferies -- Price Target Raised to $27 - GuruFocus
TNGX stock hits record high on inking collaboration deal with ERAS - MSN
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $30.1, Implies 18% Upside - TradingView
Mizuho raises Tango Therapeutics stock price target on pipeline progress - Investing.com
Tango Therapeutics Shares Fall After Jefferies Downgrade - Moomoo
Tango Therapeutics price target raised to $33 from $19 at Wedbush - TipRanks
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $27.4, Implies 7% Upside - TradingView
Tango Therapeutics Is Maintained at Outperform by Wedbush - Moomoo
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $26, Implies 2% Upside - TradingView
Tango Therapeutics downgraded to Hold from Buy at Jefferies - TipRanks
Jefferies downgrades Tango Therapeutics stock rating on valuation - Investing.com
Jefferies downgrades Tango Therapeutics stock rating on valuation By Investing.com - Investing.com Australia
Tango Therapeutics, Inc. Stock 12‑Month Price Target Raised to $24.8, Implies 3% Downside - TradingView
TNGX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocus
TNGX: Financial Update and Future Outlook - GuruFocus
Tango Therapeutics reports Q1 EPS (32c), consensus (31c) - TipRanks
Tango Therapeutics Reshapes Board Amid Late-Stage Progress - TipRanks
Tango Therapeutics Q1 net loss widens as collaboration revenue falls - TradingView
Earnings Flash (TNGX) Tango Therapeutics, Inc. Reports Q1 Revenue $0 - marketscreener.com
Tango Therapeutics (NASDAQ: TNGX) widens Q1 loss but holds $380M cash runway - Stock Titan
Tango Therapeutics (NASDAQ: TNGX) posts Q1 2026 loss but holds $380M cash runway - Stock Titan
Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights - The Manila Times
Tango Therapeutics Stock Leaps on Fresh Optimism - TipRanks
Adage (NASDAQ: TNGX) discloses 8.98% ownership of Tango Therapeutics - Stock Titan
Investors brace for Tango Therapeutics earnings amid combo hopes By Investing.com - Investing.com South Africa
Tango Therapeutics patents new HBS1L degradation inducers - BioWorld News
TradingKey - TradingKey
Farallon (TNGX) reports 9.10M shares and 2.16M warrants in amendment - Stock Titan
Stifel Remains Bullish on Tango Therapeutics (TNGX) - Insider Monkey
Tango Therapeutics (TNGX) price target increased by 11.68% to 24.38 - MSN
5 Best Performing Healthcare Stocks So Far in 2026 - Insider Monkey
Tango Therapeutics Finalizes Separation Agreement with Former CFO - TipRanks
Tango Therapeutics finalizes separation agreement with former CFO Daniella Beckman - Investing.com
Daniella Beckman exits Tango Therapeutics as CFO; separation agreement details - TradingView
CFO Daniella Beckman exit terms at Tango Therapeutics (NASDAQ: TNGX) - Stock Titan
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View - Zacks Investment Research
[SCHEDULE 13G] Tango Therapeutics, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Tango Therapeutics Insider Sold Shares Worth $573,097, According to a Recent SEC Filing - marketscreener.com
TNGX News | TANGO THERAPEUTICS INC (NASDAQ:TNGX) - ChartMill
Tango Therapeutics Inc (TNGX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Tango Therapeutics Inc 주식 (TNGX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Crystal Adam | President, R&D |
May 01 '26 |
Sale |
21.23 |
27,000 |
573,097 |
115,743 |
0.71%
자본화:
|
볼륨(24시간):